Gossamer Bio Inc. (GOSS) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, GOSS scores 33 out of 100, a letter grade of E, with the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

• Fundamental Cash Engine: 6 / 20. The rating cites ROIC of -35% and an FCF yield of 0%. Per the SEC financials, FY 2025 free cash flow was $-171.3M against revenue of $48.5M, so the business is consuming cash rather than generating it. For an investor, this pillar means the core operation is not currently self-funding.
• Whale 13F Flow: 8 / 20. The rating describes institutional accumulation and options positioning. The holdings section contains no 13F data, so the specific direction and size of institutional moves cannot be verified from the source data.
• Insider Conviction: 3 / 20. The rating cites SEC Form 4 and Congressional PTR cluster flow. The lowest pillar score in the rating reflects weak insider signaling. The holdings section contains no insider transaction records to confirm the underlying basis.
• Macro Regime Fit: 8 / 20. The rating cites a beta of 1.0 and sector sensitivity. Per the market data, beta is 1.0, meaning the stock is rated as moving in line with the broader market; the rating does not indicate a macro tailwind.
• Forensic Balance Sheet: 8 / 20. The rating cites an Altman Z-Score of 2.5, a Piotroski F-Score of 1/9, and a Debt/Equity ratio of 0.5. The low Piotroski score signals weak financial-health indicators across the nine tests.

Taken together, the pillar scores point to a company whose fundamentals and balance-sheet signals are weak, with limited insider or institutional confidence visible in the data. The implications for a prospective investor are: (1) upside depends on a turnaround in cash generation that the reported figures do not yet show; (2) the valuation is not supported by current earnings, since P/E and EPS are unavailable and operating margin is -60%; and (3) the rating frames the stock as elevated forensic risk, so downside sensitivity to further losses or financing events is a central consideration. This is an analytical reading of the source data, not personalized advice.

Gossamer Bio Inc. (GOSS) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Per the company profile, it has a market capitalization of $0.1B. Per the SEC financials, FY 2025 revenue was $48.5M, down from $114.7M in FY 2024, and FY 2023 revenue was $0.0M. The source data does not describe the specific products, customers, or revenue model.

Per the market data, gross margin is 0%, operating margin is -60%, and net margin is -60%, with ROIC at -35%. Per the RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 1/9, and Debt/Equity is 0.5. The reported losses are large relative to revenue in each period, and the FY 2025 cash balance of $37.7M sits against FY 2025 free cash flow of $-171.3M. The source data does not provide the debt amount for FY 2025.

• RISK WATCH (RED): A Yahoo Finance report headlined "Gossamer Bio (GOSS) Stock Sees Fair Value Lift As Analysts Weigh Seralutinib Risks," flagged in the news data as the highest-priority item.
• MARKET WIRE (YELLOW): Reports on estimates (TradingView), a shareholder stock issuance plan approval (The Globe and Mail), a voting-power item tied to an October meeting (Stock Titan), a quote and history page (Yahoo Finance UK), and an FDA application filing cited alongside a stock market value of USD 54.3 million (ad-hoc-news.de).
• Proprietary signals: The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals.

The stock-issuance approval is the most directly relevant catalyst for the balance sheet and existing shareholders, though the source data does not state the size or terms of the plan.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. The graph therefore does not identify upstream suppliers, downstream customers, or sector correlations for GOSS. Second-order bottlenecks cannot be mapped from the source data. The only sector context is the classification in the profile: Health Care, Biotechnology: Pharmaceutical Preparations. A prospective investor should note that the news flow references a specific pipeline asset (seralutinib) and an FDA application, which are regulatory and clinical dependencies, but the source data does not establish their dependency structure.

• What drove the revenue decline from $114.7M in FY 2024 to $48.5M in FY 2025, and what is the revenue outlook?
• What is the FY 2025 debt balance, given that the financials list it as N/A?
• What are the size and terms of the approved stock issuance plan, and how much dilution does it imply?
• What is the status and risk profile of seralutinib and the referenced FDA application?
• What specific 13F, insider, and Congressional transactions underlie the pillar scores in the RQD rating?